Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients.  Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.    

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002.  This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a libra
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MI (PRWEB) November 22, 2014 ... to simulate the proper management of life-like respiratory ... test lung devices . Grand Rapids-based, Michigan Instruments ... to donate two of the respiratory simulation units ... $15,000 each. Grand Valley and Muskegon Community College ...
(Date:11/21/2014)... HARROGATE, England , Nov. 21, 2014   TRU-D ... Ltd., will feature their superbug-killing UVC automated disinfection robot, TRU-D ... , this week from Nov. 23 to 26 at Stand ... Societies, is the United Kingdom,s largest ... 15 infection prevention societies to one of the leading events ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... Why did Stephen Hawking become so ... instantly recognizable? Why have they become icons to rival ... Hilton Ratcliffe seeks out the answers to those questions, ... do with science. In " Stephen Hawking Smoked My ... 2014), Ratcliffe puts it plainly: , “It is ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... Known medically as atopic dermatitis (AD), eczema is ... the affected area of skin may result in redness, ... of the skin.(2) Immuno-modulators called topical calcineurin (cal-SEE-nur-in) inhibitors ... moderate or severe eczema(3) who fail to respond adequately ...
... BETHESDA, Md., Aug. 3 Micromet, Inc. ... novel, proprietary antibodies for the treatment of cancer, inflammation ... Orphan Drug Designation from the European Medicines Agency (EMEA) ... (ALL). Blinatumomab is a novel therapeutic antibody that ...
... 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... relating to long-term treatment with Stimuvax were presented at ... 13th World Conference on Lung Cancer in San Francisco ... Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, ...
Cached Biology Technology:Five Questions About Protopic (tacrolimus) Ointment 2Five Questions About Protopic (tacrolimus) Ointment 3Five Questions About Protopic (tacrolimus) Ointment 4Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 4Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 2Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 3Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer 4
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... available in French . Researchers at ... of Canada, the University of Toronto and the SETI ... highly unique spring located on Axel Heiberg Island in ... explains that the Lost Hammer spring supports microbial life, ...
... 3, 2010 A cancer conference dedicated to increased ... bridge Western and Native American approaches to disease and ... Navajos are learning about cancer, adopting measures to help ... opening up to new therapies. The 3rd annual ...
... This release is available in French . , ... Social Sciences, two teams of researchers led by Professor Barbara ... Goldsmiths, University of London, U.K., have brought research in intelligent ... have developed a highly sophisticated concept of interactive clothing whereby ...
Cached Biology News:Could life survive on Mars? Yes, expert says 23rd annual Ft. Defiance Cancer Awareness Conference set for June 5 23rd annual Ft. Defiance Cancer Awareness Conference set for June 5 3Innovative research reawakens human memories through intelligent textiles 2
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Biology Products: